Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine

NCT06417775 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

496

Enrollment

INDUSTRY

Sponsor class

Conditions

Migraine

Interventions

DRUG: Ubrogepant
DRUG: Placebo for Ubrogepant

Sponsor

AbbVie